We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area. Our wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: hematology, cardiovascular disease, and rare diseases.
Zerlasiran (SLN360)
Cardiovascular Disease
Divesiran
(SLN124)
Polycythemia Vera (PV)
Multiple Hematologic Conditions
SLN548
Complement-Mediated Diseases
Multiple programs
Undisclosed
1Licensed to AstraZeneca with milestones and royalities